Akesobio readies Hong Kong listing
Chinese biopharmaceutical firm Akesobio has got the greenlight from the Hong Kong Stock Exchange for its IPO, which is expected to raise $200m to $300m, according to a source familiar with the matter.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: